Cargando…

Cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas

BACKGROUND: Malignant vascular tumors (MVTs) are rare and often misdiagnosed due to wide range of clinical presentations, varied histology, and exquisite imagining features. We aim to characterize two different types of MVTs of the liver: hepatic angiosarcomas (HA) and hepatic epithelioid hemangioen...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez, Constanza, Lai, Jonathan K., Ramai, Daryl, Facciorusso, Antonio, Gao, Zu‐Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683533/
https://www.ncbi.nlm.nih.gov/pubmed/34850580
http://dx.doi.org/10.1002/cam4.4403
_version_ 1784617441243955200
author Martínez, Constanza
Lai, Jonathan K.
Ramai, Daryl
Facciorusso, Antonio
Gao, Zu‐Hua
author_facet Martínez, Constanza
Lai, Jonathan K.
Ramai, Daryl
Facciorusso, Antonio
Gao, Zu‐Hua
author_sort Martínez, Constanza
collection PubMed
description BACKGROUND: Malignant vascular tumors (MVTs) are rare and often misdiagnosed due to wide range of clinical presentations, varied histology, and exquisite imagining features. We aim to characterize two different types of MVTs of the liver: hepatic angiosarcomas (HA) and hepatic epithelioid hemangioendotheliomas (HEHE). METHODS: Data on HA and HEHE between 1975 and 2016 were extracted from the SEER database and analyzed. RESULTS: A total of 366 patients with HA were identified where 64.2% were male and 79% of White race. The median age at diagnosis was 64 ± 16.2 years. Distant metastasis was found in 24% of patients, regional disease in 22.1%, and localized disease in 21.3%. The median overall survival for HA was 2 months. For HEHE, 120 cases were identified, 32.5% were male and 80% of White race. The median age of diagnosis was 51 ± 16.8 years. Distant metastasis was found in 37.5% of patients, regional disease in 27.5%, and localized disease in 20%. The median overall survival was 182 months. CONCLUSION: Patients’ demographics such as race, age, and gender may assist in elucidating distinct subtypes of MVTs. HA is an aggressive tumor despite intervention. Patients with HEHE tumors have significantly better survival compared to patients with HA. Further studies are needed to deepen our knowledge about the histopathology of these tumors, the outcomes of liver transplantation as a therapeutic alternative, and available molecular targets for MVTs.
format Online
Article
Text
id pubmed-8683533
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86835332021-12-30 Cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas Martínez, Constanza Lai, Jonathan K. Ramai, Daryl Facciorusso, Antonio Gao, Zu‐Hua Cancer Med Clinical Cancer Research BACKGROUND: Malignant vascular tumors (MVTs) are rare and often misdiagnosed due to wide range of clinical presentations, varied histology, and exquisite imagining features. We aim to characterize two different types of MVTs of the liver: hepatic angiosarcomas (HA) and hepatic epithelioid hemangioendotheliomas (HEHE). METHODS: Data on HA and HEHE between 1975 and 2016 were extracted from the SEER database and analyzed. RESULTS: A total of 366 patients with HA were identified where 64.2% were male and 79% of White race. The median age at diagnosis was 64 ± 16.2 years. Distant metastasis was found in 24% of patients, regional disease in 22.1%, and localized disease in 21.3%. The median overall survival for HA was 2 months. For HEHE, 120 cases were identified, 32.5% were male and 80% of White race. The median age of diagnosis was 51 ± 16.8 years. Distant metastasis was found in 37.5% of patients, regional disease in 27.5%, and localized disease in 20%. The median overall survival was 182 months. CONCLUSION: Patients’ demographics such as race, age, and gender may assist in elucidating distinct subtypes of MVTs. HA is an aggressive tumor despite intervention. Patients with HEHE tumors have significantly better survival compared to patients with HA. Further studies are needed to deepen our knowledge about the histopathology of these tumors, the outcomes of liver transplantation as a therapeutic alternative, and available molecular targets for MVTs. John Wiley and Sons Inc. 2021-12-01 /pmc/articles/PMC8683533/ /pubmed/34850580 http://dx.doi.org/10.1002/cam4.4403 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Martínez, Constanza
Lai, Jonathan K.
Ramai, Daryl
Facciorusso, Antonio
Gao, Zu‐Hua
Cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas
title Cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas
title_full Cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas
title_fullStr Cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas
title_full_unstemmed Cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas
title_short Cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas
title_sort cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683533/
https://www.ncbi.nlm.nih.gov/pubmed/34850580
http://dx.doi.org/10.1002/cam4.4403
work_keys_str_mv AT martinezconstanza cancerregistrystudyofmalignanthepaticvasculartumorshepaticangiosarcomasandhepaticepithelioidhemangioendotheliomas
AT laijonathank cancerregistrystudyofmalignanthepaticvasculartumorshepaticangiosarcomasandhepaticepithelioidhemangioendotheliomas
AT ramaidaryl cancerregistrystudyofmalignanthepaticvasculartumorshepaticangiosarcomasandhepaticepithelioidhemangioendotheliomas
AT facciorussoantonio cancerregistrystudyofmalignanthepaticvasculartumorshepaticangiosarcomasandhepaticepithelioidhemangioendotheliomas
AT gaozuhua cancerregistrystudyofmalignanthepaticvasculartumorshepaticangiosarcomasandhepaticepithelioidhemangioendotheliomas